Thomas S. Uldrick, M.D.
Thomas S. Uldrick, M.D.
Staff Clinician

Dr. Uldrick develops and directs early phase clinical studies and biomarker-driven natural history studies in KSHV-associated malignancies and cancer in people with HIV, including Kaposi sarcoma, multicentric Castleman disease, primary effusion lymphoma, primary CNS lymphoma, and anal cancer. He has published important studies on the pathogenesis of IL-6 related syndromes in the setting of HIV and KSHV co-infection, and HIV-associated cancers in resource-limited settings. Current therapeutic studies incorporate cytokine and growth factor manipulation, immune modulation, and targeting of reservoirs of gamma-herpesvirus infected lymphoid cells using monoclonal antibodies or virus activated cytotoxic therapy.

Areas of Expertise
KSHV, lymphoma, cancer in people with HIV, immunotherapy, global health

Contact Info

Thomas S. Uldrick, M.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 6N106
Bethesda, MD 20892
301-402-6296
uldrickts@mail.nih.gov
Link to Clinicaltrials.gov Protocol ID Referral Phone

Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Multicentric Castleman Disease 

NCI-11-C-0233 301-496-8959

Dr. Uldrick's major research interests are the natural history and management of virally associated malignancies that occur in the setting of HIV/AIDS and other immune disorders. Therapeutic studies focus on novel approaches to the treatment of several viral-associated malignancies using approaches that incorporate cytokine and growth factor manupulation and targeting of reservoirs of gamma-herpesvirus infected lymphoid cells using monoclonal antobodies or virus activated cytotoxic therapy.

Active projects include: (1) Evaluation of the natural history of KSHV-associated disorders, including Kaposi sarcoma, KSHV-associated multicentric Castleman disease, primary effusion lymphoma, and a novel entity we described, KSHV-associated Inflammatory Cytokine Syndrome (KICS) (2) Early-phase treatment studies in KSHV-associated malignancies employing immune modulating, anti-angiogenic and virus-activated cytotoxic therapies (3) Evaluation of radiation-sparing approaches for HIV-associated primary CNS lymphoma, with an emphasis on long-term survival and neurocognitive functioning (4) Evaluation of human genomic alterations and gut associated lymphoid tissue in patients with anal cancer

Current collaborators include: Deborah Citrin, Radiation Oncology Branch, NCI Nancy Hessol, UCSF Frank Maldarelli, Drug Resistance Program, NCI Anisa Mosam, University of KwaZulu-Natal, South Africa Irini Sereti, Laboratory of Immunoregulation, NIAID Giovanna Tosato, Laboratory of Cellular Oncology, NCI Denise Whitby, Viral Oncology Section, NCI-Frederick HIV+ Tumor Molecular Characterization Project, Office of Cancer Genomics, NCI

Selected Publications
  1. Uldrick TS, Polizzotto MN, Aleman K, O'Mahony D, Wyvill KM, Wang V, Marshall V, Pittaluga S, Steinberg SM, Tosato G, Whitby D, Little RF, Yarchoan R.
    Blood. 117: 6977-86, 2011. [ Journal Article ]
  2. Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R.
    J. Clin. Oncol.. 30: 1476-83, 2012. [ Journal Article ]
  3. Uldrick TS, Pipkin S, Scheer S, Hessol NA.
    AIDS. 28: 397-405, 2014. [ Journal Article ]
  4. Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM.
    J. Acquir. Immune Defic. Syndr.. 60: 150-7, 2012. [ Journal Article ]
  5. Uldrick TS, Wang V, O'Mahony D, Aleman K, Wyvill KM, Marshall V, Steinberg SM, Pittaluga S, Maric I, Whitby D, Tosato G, Little RF, Yarchoan R.
    Clin. Infect. Dis.. 51: 350-8, 2010. [ Journal Article ]

Dr. Uldrick received his B.A. from the University of California at Berkeley, and his M.D. from the State University of New York, Downstate. He trained in internal medicine, hematology, and medical oncology at Columbia University. At Columbia, he completed an M.S. in biostatistics, with a focus on patient-oriented research, under a scholarship funded by an NIH-sponsored Clinical and Translational Science Award. Through the NIH-sponsored Fogarty program, he collaborated with Kaposi sarcoma (KS) researchers in South Africa on issues related to treatment of advanced KS in resource-limited settings. He has served on the NCI Lymphoma Steering Committee Primary Central Nervous System Lymphoma Working Group and participates on the AIDS Clinical Trials Group Independent Endpoint Review Committee for trials investigating KS therapies in sub-Saharan Africa.

Clinical Trials

Link to Clinicaltrials.gov Protocol ID Referral Phone

Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Multicentric Castleman Disease 

NCI-11-C-0233 301-496-8959

Research

Dr. Uldrick's major research interests are the natural history and management of virally associated malignancies that occur in the setting of HIV/AIDS and other immune disorders. Therapeutic studies focus on novel approaches to the treatment of several viral-associated malignancies using approaches that incorporate cytokine and growth factor manupulation and targeting of reservoirs of gamma-herpesvirus infected lymphoid cells using monoclonal antobodies or virus activated cytotoxic therapy.

Active projects include: (1) Evaluation of the natural history of KSHV-associated disorders, including Kaposi sarcoma, KSHV-associated multicentric Castleman disease, primary effusion lymphoma, and a novel entity we described, KSHV-associated Inflammatory Cytokine Syndrome (KICS) (2) Early-phase treatment studies in KSHV-associated malignancies employing immune modulating, anti-angiogenic and virus-activated cytotoxic therapies (3) Evaluation of radiation-sparing approaches for HIV-associated primary CNS lymphoma, with an emphasis on long-term survival and neurocognitive functioning (4) Evaluation of human genomic alterations and gut associated lymphoid tissue in patients with anal cancer

Current collaborators include: Deborah Citrin, Radiation Oncology Branch, NCI Nancy Hessol, UCSF Frank Maldarelli, Drug Resistance Program, NCI Anisa Mosam, University of KwaZulu-Natal, South Africa Irini Sereti, Laboratory of Immunoregulation, NIAID Giovanna Tosato, Laboratory of Cellular Oncology, NCI Denise Whitby, Viral Oncology Section, NCI-Frederick HIV+ Tumor Molecular Characterization Project, Office of Cancer Genomics, NCI

Publications

Selected Publications
  1. Uldrick TS, Polizzotto MN, Aleman K, O'Mahony D, Wyvill KM, Wang V, Marshall V, Pittaluga S, Steinberg SM, Tosato G, Whitby D, Little RF, Yarchoan R.
    Blood. 117: 6977-86, 2011. [ Journal Article ]
  2. Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R.
    J. Clin. Oncol.. 30: 1476-83, 2012. [ Journal Article ]
  3. Uldrick TS, Pipkin S, Scheer S, Hessol NA.
    AIDS. 28: 397-405, 2014. [ Journal Article ]
  4. Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM.
    J. Acquir. Immune Defic. Syndr.. 60: 150-7, 2012. [ Journal Article ]
  5. Uldrick TS, Wang V, O'Mahony D, Aleman K, Wyvill KM, Marshall V, Steinberg SM, Pittaluga S, Maric I, Whitby D, Tosato G, Little RF, Yarchoan R.
    Clin. Infect. Dis.. 51: 350-8, 2010. [ Journal Article ]

Biography

Dr. Uldrick received his B.A. from the University of California at Berkeley, and his M.D. from the State University of New York, Downstate. He trained in internal medicine, hematology, and medical oncology at Columbia University. At Columbia, he completed an M.S. in biostatistics, with a focus on patient-oriented research, under a scholarship funded by an NIH-sponsored Clinical and Translational Science Award. Through the NIH-sponsored Fogarty program, he collaborated with Kaposi sarcoma (KS) researchers in South Africa on issues related to treatment of advanced KS in resource-limited settings. He has served on the NCI Lymphoma Steering Committee Primary Central Nervous System Lymphoma Working Group and participates on the AIDS Clinical Trials Group Independent Endpoint Review Committee for trials investigating KS therapies in sub-Saharan Africa.